Key Figures


Staff 150
Products in development 16
Partnered products 4
Cash for operations CHF 104.8 million

(plus $ 100 million upfront from Takeda)

Funding into 2027

(assumes second ACI-35-related milestone payment of CHF25 million received in 2025 and no other milestones)

Debt None
Shares outstanding 99.4 million

(as of March 31, 2024; excluding treasury shares)

Potential total milestones from partners CHF 4.3 billion